HROW — Harrow, Inc.
$30.12
+$1.82 (+6.43%)
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Market Cap
$1.13B
Forward P/E
14.4x
52-Week Range
N/A
HROW Price History
Revenue vs. Net Income
$272M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$42.8M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
7.5%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.2x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.4%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+3.1%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
